Bristol Myers Squibb on Friday sued the Biden administration over Medicare’s new powers to negotiate drug prices, the third such lawsuit to be filed against the program in a matter of days.
The lawsuit, filed in federal district court in New Jersey, argues the Medicare negotiations violate the First and Fifth Amendments of the U.S. Constitution.
Bristol Myers Squibb has asked the court to declare the program unconstitutional and prevent the Health and Human Services Department from forcing the company to enter negotiations.
The drugmaker said its blood thinner Eliquis, used to treat clots and strokes, will be subject to the negotiations this year. Bristol Myers Squibb generated $11.8 billion in revenue from Eliquis last year, about 25% of the company’s $46 billion in total revenue for 2022.
The pharmaceutical company said Opdivo, used to treat several types of cancer, will be subject to the Medicare negotiations in the future. Opdivo generated $8.2 billion in sales for the company in 2022, which made up about 18% of the drugmaker’s total revenue for that year.
Bristol Myer Squibb’s arguments mirror those lodged by drugmaker Merck last week, which was the first company to sue the federal government over the drug negotiations.
The U.S. Chamber of Commerce has also sued HHS over the program with similar arguments.
This is breaking news. Please check back for updates.
Discussion about this post